Pharmaceutical Fraud Cases: The Business Decisions Behind the Settlements

Pharmaceutical fraud cases expose how drug companies and their healthcare intermediaries allegedly turn pricing reports, prescription incentives and product records into government payments they should not receive or rebates they should have paid. A hospital gets a discount that Medicaid never sees. A doctor gets paid for a talk that never happens. A pharmacy wins referrals by keeping patients on a drug. Taxpayers pay for the inflated claims and the rebates withheld. If you work in pricing, sales, patient support or quality, the business decision behind the settlement may be familiar.

Pricing Cases Turn on the Number Reported

Drug-pricing cases often begin inside the manufacturer’s own calculations. Average manufacturer price is the average paid to a manufacturer for drugs distributed to retail pharmacies. Best Price is the lowest qualifying price the manufacturer offers specified buyers. Both help determine Medicaid rebates. Average sales price weights sales by volume and helps determine Medicare Part B payments. Average wholesale price is a privately published benchmark.

Mylan’s EpiPen Classification

Mylan agreed to a $465 million settlement in August 2017 over allegations that it reported EpiPen as a generic drug despite the absence of a therapeutically equivalent drug. The Department of Justice alleged that the classification let Mylan avoid the corresponding brand-drug and inflation rebates while raising private-market prices.

The issue was the category assigned to the drug in Medicaid reporting. That category changed the rebate owed on prescriptions the program had already paid for. Someone responsible for product data or rebate calculations could see the discrepancy without ever handling a prescription claim.

Wyeth’s Hospital Discounts and Mallinckrodt’s New Base Date

Wyeth and Pfizer agreed to a $784.6 million settlement in April 2016 over allegedly concealed bundled discounts on oral and intravenous Protonix. The government’s account explains the commercial logic: discounted hospital use could start patients on oral Protonix, which they would continue taking after discharge while Medicaid and other payers paid nearly full price.

The alleged concealment kept those hospital discounts out of Medicaid’s Best Price calculation. The hospital contract bought access to future prescriptions, and the government allegedly lost the rebate that should have followed the discount.

Mallinckrodt’s Acthar case concerned a different input: the starting price used to measure inflation. The government alleged that Mallinckrodt and its predecessor, Questcor, calculated rebates as though Acthar were newly marketed in 2013, erasing earlier price increases from the calculation. In its March 2022 settlement, Mallinckrodt admitted that Acthar had been approved and marketed before 1990 and agreed to correct the base date. Approximately $234.7 million of that settlement addressed the rebate allegations. An old drug had acquired a new starting point on the rebate paperwork.

A Published Price Can Become a Sales Incentive

Compounding suppliers can sell an ingredient on the reimbursement it attracts. In Fagron’s $22.05 million settlement in November 2019, the government alleged that inflated ingredient prices were reported and the resulting reimbursement spread was marketed to compounding pharmacies. Freedom, an ingredient supplier in the case, allegedly reported fluticasone at $3,500 per gram while typically selling it for $160. The ingredient was cheap. The reported price made it look expensive to the payer.

The Pricing Error Can Reach Another Program

The 340B ceiling price draws on average manufacturer price and the Medicaid rebate calculation. A concealed discount can therefore affect both a state’s rebate and what a safety-net provider pays. In the Aventis private-label discount settlement, the government alleged underpaid Medicaid rebates and overcharges to Public Health Service purchasers from the same pricing practice.

Service Fees Can Move Prices in Opposite Directions

A whistleblower’s case led to the government’s April 2024 complaint against Regeneron. The government alleged that Regeneron paid credit-card processing costs for physicians buying Eylea but did not count those payments as price concessions. That allegedly left average sales price too high and increased Medicare Part B reimbursements. The physician got the purchasing benefit, while the reported price omitted it.

Bristol-Myers Squibb’s $75 million settlement in April 2021 concerned alleged underreporting of average manufacturer price. The government alleged that it improperly deducted wholesaler service fees and left out value received through price-appreciation clauses. Those clauses let the manufacturer recapture part of the gain on inventory a wholesaler held when the list price rose. The alleged understatement reduced Medicaid rebates. In one case, the reported price was allegedly too high. In the other, too low. Both favored the manufacturer because the programs used those prices differently.

What Is Considered Off-Label Promotion?

Off-label promotion means promoting a drug for a use beyond its approved labeling. The pharmaceutical whistleblower cases below connect the manufacturer’s promotion to claims for uses government programs did not cover, sometimes alongside payments intended to influence prescribing.

Eli Lilly’s January 2009 Zyprexa civil settlement provided up to $800 million over alleged promotion for noncovered uses, including dementia. Former sales representatives brought the qui tam cases.

Pfizer’s September 2009 civil False Claims Act settlement addressed alleged noncovered promotion of Bextra, Geodon, Zyvox and Lyrica, along with alleged prescription-inducing kickbacks. The marketing message and the payment to the prescriber appeared together in the same case.

AstraZeneca reached an April 2010 civil settlement involving Seroquel. The allegations included payments to physicians recruited as authors of company-prepared articles. A sales message could arrive wearing the authority of a medical publication.

Speaker Fees for Talks Nobody Heard

Salix’s June 2016 civil settlement was $54 million, with extensive admissions. Salix admitted that prerecorded presentations were sometimes never played, or were played where attendees could not readily see or hear them. Speakers could receive honoraria even when nobody called them for the planned discussion afterward.

The attendance records served another purpose. Salix admitted that sales representatives listed physicians who had not attended to make the cost per person appear lower. The company’s meal limit remained on paper. The guest list changed to get around it.

Payments Could Buy Influence Beyond the Doctor

Johnson & Johnson’s November 2013 civil settlement concerning Omnicare was $149 million. The government alleged that market-share rebates, data purchases, grants and educational funding induced the pharmacy’s consultant pharmacists to recommend the company’s drugs. The person influencing the prescription could sit inside an institutional pharmacy.

Copay Cases Follow the Donation Back to the Drug

Copay-foundation cases concern alleged arrangements in which manufacturers funded patients’ Medicare cost sharing through charities while directing the benefit toward their own products. The fund’s eligibility rules, donation timing and patient information explain how a payment called charitable assistance could support the donor’s drug revenue.

United Therapeutics agreed to a $210 million civil settlement in December 2017. The government alleged that it obtained drug-specific spending data from a foundation and used those data to decide how much to donate. It also allegedly kept needy Medicare patients out of its free-drug program while that program remained open to other financially needy patients. The foundation paid the copay, and Medicare paid for the drug.

Actelion’s $360 million civil settlement in December 2018 concerned the same broad channel for pulmonary arterial hypertension drugs. The government alleged that Actelion continued receiving information despite the foundation’s warning against it.

The Pharmacy That Timed the Applications

Advanced Care Scripts acknowledged coordinating information between foundations and Teva. It relayed data that let Teva correlate donations with spending on Copaxone patients. When funds closed to new applications, the pharmacy reported how many eligible Copaxone patients were waiting. When a fund reopened, it promptly submitted a batch consisting almost entirely of their applications.

Benefits investigation gave the pharmacy the patient information, and advance knowledge of funding let it time the submissions. Teva’s October 2024 copay settlement was $425 million, resolving allegations that it used foundations and a specialty pharmacy to direct assistance to Copaxone patients.

Specialty-Pharmacy Cases Turn Refills Into Referrals

Novartis’s Exjade and Myfortic case concerned alleged rewards to specialty pharmacies for influencing continued treatment or switching drugs. Its November 2015 civil False Claims Act settlement addressed incentives linking the manufacturer to the pharmacies counseling patients.

Accredo’s admissions in its separate settlement described Exjade scorecards measuring how long patients continued ordering refills. The scores did not exclude patients who stopped because of side effects or because their physicians told them to stop. Higher scores brought a larger share of patient referrals.

The government’s complaint described the pressure on BioScrip directly:

A refill score could reward persistence even when treatment had ended for a medical reason. In the Myfortic part of the case, the government alleged that rebates bought pharmacy recommendations to switch patients from competing drugs. The counseling script, scorecard and referral allocation explained what the manufacturer was buying.

PBM Cases Follow What Happened to the Rebate

A manufacturer rebate can buy preferred placement on a pharmacy benefit manager’s drug list. The price on the pharmacy claim and the concession later received by the plan are different parts of that transaction.

In July 2024, Rite Aid and Elixir agreed to pay $101 million to resolve allegations about Medicare Part D reporting. The government alleged that retained manufacturer rebates had been labeled service fees even though manufacturers had not negotiated those fees. Elixir allegedly knew the retained amounts did not qualify for that treatment. The settlement also provided a separate $20 million bankruptcy claim.

The alleged mislabeling mattered because Part D reporting gives the government the benefit of manufacturer price concessions. The service-fee description kept part of the rebate out of that accounting. Contracts, rebate reconciliations and reports to Medicare show different stages of the same money flow.

The USC Schaeffer Center’s 2020 paper, The Association Between Drug Rebates and List Prices, studied list and estimated net prices for branded drugs during 2015 through 2018. The paper drew this inference from the association it found:

The paper measured rebates as the difference between list and estimated net prices, including concessions to intermediaries beyond PBMs. That distinction matters to someone who handles the contracts: the headline discount leaves unanswered who received it and how it was reported.

Quality and Billing Cases Follow the Product Into the Claim

Manufacturing cases connect what left the plant to what government health care programs paid for. GlaxoSmithKline’s October 2010 Cidra civil settlement provided $600 million over claims for allegedly adulterated Kytril, Bactroban, Paxil CR and Avandamet.

The whistleblower’s complaint alleged product mix-ups, contamination and a striking approach to documenting problems:

The alleged practice removed the written account after the discussion. For a quality employee, the batch records, audit findings and decisions to release product explain what reached patients. Ranbaxy’s May 2013 civil settlement was $350 million over alleged false claims for drugs made at its Paonta Sahib and Dewas facilities. A former executive brought that case.

AmerisourceBergen’s October 2018 civil settlement concerned alleged repackaging of oncology-supportive drugs into prefilled syringes, profits from overfill, double billing and kickbacks. Extra medicine inside a vial became another source of revenue through the repackaging operation.

Drug-safety representations can also affect government payments. GlaxoSmithKline’s July 2012 civil settlement addressed alleged misrepresentations about Avandia’s safety.

Scientific records can reach a government payment before a drug reaches the market. Athira Pharma’s January 2025 settlement resolved allegations that it failed to report research-misconduct allegations in National Institutes of Health grant applications, progress reports and assurances. The government payment at issue was the grant.

Generic Price-Fixing Cases Concern the Actual Selling Price

Generic price-fixing cases concern alleged agreements among competitors to raise prices or divide customers, causing government programs to pay more. The comparison runs through competitor communications, customer allocation and the prices actually charged.

Sandoz agreed to a $185 million civil False Claims Act settlement in October 2021 over alleged anticompetitive payments and generic-drug pricing arrangements. Teva’s October 2024 price-fixing settlement required a separate $25 million payment over alleged arrangements with competitors. That payment addressed generic pricing, while its Copaxone settlement addressed copay assistance.

What Is an Example of a Pharmaceutical Whistleblower Case?

Mylan’s EpiPen case is an example brought by a competitor: Sanofi-Aventis US brought the case as the whistleblower and was awarded approximately $38.7 million as its share of the federal recovery. The Lilly cases came from sales representatives, and Ranbaxy’s came from a former executive.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Our whistleblower experts build your case around the transaction you understand, whether it is a rebate calculation, speaker payment, foundation communication, refill instruction or product record.

You Know the Business Behind the Number

If the calculation, incentive or product record looks familiar, speak to one of our pharmaceutical whistleblower experts about what you’ve seen. We develop the case strategy with you, bring in pharmaceutical fraud whistleblower lawyers who understand the payment system and the evidence, and stay beside you through the decisions ahead.